TW202334148A - 用於治療弗里德希氏共濟失調（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之化合物及方法 - Google Patents

用於治療弗里德希氏共濟失調（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之化合物及方法 Download PDF

Info

Publication number
TW202334148A
TW202334148A TW112100613A TW112100613A TW202334148A TW 202334148 A TW202334148 A TW 202334148A TW 112100613 A TW112100613 A TW 112100613A TW 112100613 A TW112100613 A TW 112100613A TW 202334148 A TW202334148 A TW 202334148A
Authority
TW
Taiwan
Prior art keywords
optionally substituted
group
alkyl
compound
formula
Prior art date
Application number
TW112100613A
Other languages
English (en)
Chinese (zh)
Inventor
阿西姆 安薩里
阿巴希 巴特
肖恩 杰弗里斯
普拉蒂克 沙
承智 張
Original Assignee
美商規劃醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商規劃醫療公司 filed Critical 美商規劃醫療公司
Publication of TW202334148A publication Critical patent/TW202334148A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW112100613A 2022-01-06 2023-01-06 用於治療弗里德希氏共濟失調（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之化合物及方法 TW202334148A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263297090P 2022-01-06 2022-01-06
US63/297,090 2022-01-06
US202263382854P 2022-11-08 2022-11-08
US63/382,854 2022-11-08

Publications (1)

Publication Number Publication Date
TW202334148A true TW202334148A (zh) 2023-09-01

Family

ID=87074158

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112100613A TW202334148A (zh) 2022-01-06 2023-01-06 用於治療弗里德希氏共濟失調（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之化合物及方法

Country Status (14)

Country Link
US (1) US20250109132A1 (https=)
EP (1) EP4460302A4 (https=)
JP (1) JP2025502064A (https=)
KR (1) KR20240138079A (https=)
AU (1) AU2023205889A1 (https=)
CA (1) CA3246468A1 (https=)
CL (1) CL2024002029A1 (https=)
CO (1) CO2024010651A2 (https=)
CR (1) CR20240321A (https=)
IL (1) IL314006A (https=)
MX (1) MX2024008474A (https=)
PE (1) PE20241730A1 (https=)
TW (1) TW202334148A (https=)
WO (1) WO2023133284A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025076181A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease
WO2025076219A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease
WO2025076236A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CN106068266A (zh) * 2013-10-11 2016-11-02 千叶县 以癌症驱动基因的基因突变为靶点进行烷基化的新型烷基化剂
US11759533B2 (en) * 2017-03-29 2023-09-19 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
WO2020253711A1 (zh) * 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
KR102677015B1 (ko) * 2019-07-02 2024-06-19 누베이션 바이오 인크. Bet 억제제로서의 헤테로시클릭 화합물
JP2024502469A (ja) * 2021-01-08 2024-01-19 デザイン セラピューティクス，インク． フリードライヒ運動失調症を治療するための方法及び化合物

Also Published As

Publication number Publication date
WO2023133284A3 (en) 2023-08-24
CO2024010651A2 (es) 2024-08-08
CA3246468A1 (en) 2023-07-13
AU2023205889A1 (en) 2024-08-15
CR20240321A (es) 2024-10-16
EP4460302A2 (en) 2024-11-13
CL2024002029A1 (es) 2024-11-04
JP2025502064A (ja) 2025-01-24
KR20240138079A (ko) 2024-09-20
MX2024008474A (es) 2024-07-12
US20250109132A1 (en) 2025-04-03
IL314006A (en) 2024-08-01
PE20241730A1 (es) 2024-08-19
EP4460302A4 (en) 2025-12-24
WO2023133284A2 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
TW202334148A (zh) 用於治療弗里德希氏共濟失調（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之化合物及方法
US20240050576A1 (en) Methods and compounds for the treatment of genetic disease
EP4234553A2 (en) Methods and compounds for the treatment of genetic disease
US20240166693A1 (en) Methods and compounds for modulating myotonic dystropy 1
EP4384506A1 (en) Process for polyamide synthesis
TW202241892A (zh) 用於治療弗里德希氏運動失調症（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之方法及化合物
US20240042046A1 (en) Methods and compounds for modulating huntington's disease
EP4234550A2 (en) Methods and compounds for the treatment of genetic disease
US20230285569A1 (en) Methods and compounds for the treatment of fragile x
HK40116639A (zh) 用於治疗弗里德希共济失调的化合物和方法
CN118695861A (zh) 用于治疗弗里德希共济失调的化合物和方法
EA049760B1 (ru) Соединения и способы лечения атаксии фридрейха
HK40103182A (zh) 用於治疗弗里德希氏共济失调的方法和化合物
HK40104905A (zh) 用於调节强直性肌营养不良1型的方法和化合物
TW202517280A (zh) 用於調節亨丁頓氏舞蹈症之方法及化合物